{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T11:51:15Z","timestamp":1780487475753,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CytoSorbents Corporation and CytoSorbents Medical Inc.","award":["2025-006"],"award-info":[{"award-number":["2025-006"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Blood purification techniques are being investigated as adjunctive options in critically ill patients not only to treat severe inflammation but also to remove harmful substances such as myoglobin in rhabdomyolysis. Yet, the available evidence is limited, and further research is needed to clarify their clinical benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The international prospective COSMOS Registry (NCT05146336, 23 Nov 2021) tracks CytoSorb\u00ae (CS) utilization patterns and outcomes in critical care settings. Clinical assessment was performed before, during, and after CS treatment, with a 90-day follow-up. Device-related adverse effects were reported by investigators as the safety evaluation. Data were analyzed according to a pre-specified statistical plan using descriptive statistics and paired tests to compare pre- and post-treatment values, with subgroup and safety analyses performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 300 adult patients (30.3% female, mean age 59\u2009\u00b1\u200915 years) from 22 sites were included in this analysis. The most common indications for CS therapy (multiple indications possible per patient) were septic shock (48.3%), rhabdomyolysis (12.8%), cardiogenic shock (11.5%), liver failure (11.5%), and acute respiratory distress syndrome (ARDS; 5.0%). On average, each patient received 3.3\u2009\u00b1\u20093.3 adsorbers, with 27.9% of patients receiving 4 or more adsorbers. CS was integrated in conjunction with kidney replacement therapy (75.6%), standalone hemoperfusion (7.1%), intermittent hemodialysis (IHD; 10.6%), extracorporeal membrane oxygenation (ECMO; 3.9%), and sustained low-efficiency daily dialysis (SLEDD; 4.9%). At baseline, median (interquartile range, IQR) APACHE II and SOFA scores were 24 [18, 30] and 12 [9, 15], respectively. Fluid balance improved from +1675 [141, 3348] mL pre-CS to +115 [\u22121100, 1495] mL post-CS, and norepinephrine requirements decreased from 0.21 [0.09, 0.40] \u00b5g\/kg\/min to 0.08 [0.02, 0.22] \u00b5g\/kg\/min (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001 for both). Ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration (P\/F ratio) improved from 120 [72, 208] to 176 [115, 255] (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001). Platelet counts decreased from 123 [76, 185] to 72 [42, 118]\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), while albumin levels remained stable from 2.6 [2.3, 3.1] to 2.5 [2.3, 3.0] g\/dL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.112). ICU mortality was 33.1%, which was lower than mortality estimates historically associated with comparable APACHE II and SOFA scores. No serious adverse effects related to the device or device deficiencies were reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world CytoSorb\u00ae use as part of standard care in critically ill patients was associated with improvements in several clinical and laboratory parameters; however, these findings should be interpreted cautiously given the observational design and absence of a control group. Observed mortality was lower than mortality estimates historically associated with established severity scores.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s44158-026-00362-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T02:05:00Z","timestamp":1771985100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The international, prospective COSMOS (CytOSorb\u00ae TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients"],"prefix":"10.1186","volume":"6","author":[{"given":"Ricard","family":"Ferrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Thielmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Unglaube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirschning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Kreutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Tyczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Henzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Scharf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuno","family":"Germano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bellgardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aschraf","family":"El-Essawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Hohlstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guenther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Christian","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Aucella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Marquez","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Koestenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bottari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Hidalgo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Teboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Tomescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Klaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Scheier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N.","family":"Deliargyris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Silvio","family":"Taccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"362_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04391-z","volume":"27","author":"A Jansen","year":"2023","unstructured":"Jansen A, Waalders NJB, van Lier DPT, Kox M, Pickkers P (2023) CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care 27(1):117","journal-title":"Crit Care"},{"issue":"9","key":"362_CR2","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1046\/j.1525-1594.2003.07289.x","volume":"27","author":"C Ronco","year":"2003","unstructured":"Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V et al. (2003) Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 27(9):792\u2013801","journal-title":"Artif Organs"},{"issue":"1","key":"362_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/cc9411","volume":"15","author":"T Rimmele","year":"2011","unstructured":"Rimmele T, Kellum JA (2011) Clinical review: blood purification for sepsis. Crit Care 15(1):205","journal-title":"Crit Care"},{"issue":"8","key":"362_CR4","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0391398820981383","volume":"44","author":"D Tomescu","year":"2021","unstructured":"Tomescu D, Popescu M, David C, Sima R, Dima S (2021) Haemoadsorption by CytoSorb(R) in patients with acute liver failure: a case series. Int J Artif Organs 44(8):560\u2013564","journal-title":"Int J Artif Organs"},{"issue":"2","key":"362_CR5","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2259231","volume":"45","author":"C Grafe","year":"2023","unstructured":"Grafe C, Liebchen U, Greimel A, Maciuga N, Bruegel M, Irlbeck M et al. (2023) The effect of cytosorb(R) application on kidney recovery in critically ill patients with severe rhabdomyolysis: a propensity score matching analysis. Ren Fail 45(2):2259231","journal-title":"Ren Fail"},{"issue":"11","key":"362_CR6","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS (2018) Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 35(11):1763\u20131774","journal-title":"Adv Ther"},{"key":"362_CR7","unstructured":"International Organization for Standardization (ISO). ISO 14155:2020 clinical investigation of medical devices for human subjects \u2014 good clinical practice. https:\/\/www.iso.org\/standard\/71690.html; 2020."},{"key":"362_CR8","doi-asserted-by":"publisher","DOI":"10.2196\/55880","volume":"13","author":"FS Taccone","year":"2024","unstructured":"Taccone FS, Brunkhorst FM, Bottari G, Hidalgo J, Kribben A, Teboul JL et al. (2024) The COSMOS registry of CytoSorb hemoadsorption therapy in critically ill patients: protocol for an international, prospective registry. JMIR Res Protoc 13:e55880","journal-title":"JMIR Res Protoc"},{"issue":"23","key":"362_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12237199","volume":"12","author":"S Mitzner","year":"2023","unstructured":"Mitzner S, Kogelmann K, Ince C, Molnar Z, Ferrer R, Nierhaus A (2023) Adjunctive hemoadsorption therapy with CytoSorb in patients with septic\/vasoplegic shock: a best practice consensus statement. J Clin Med 12(23):7199","journal-title":"J Clin Med"},{"issue":"1","key":"362_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12882-024-03679-8","volume":"25","author":"L Forni","year":"2024","unstructured":"Forni L, Aucella F, Bottari G, Buttner S, Cantalchar\"03C0 V, Fries D et al. (2024) Hemoadsorption therapy for myoglobin removal in rhabdomyolysis: consensus of the hemoadsorption in rhabdomyolysis task force. BMC Nephrol 25(1):247.","journal-title":"BMC Nephrol"},{"issue":"1","key":"362_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61658-3","volume":"14","author":"P Haselwanter","year":"2024","unstructured":"Haselwanter P, Scheiner B, Balcar L, Semmler G, Riedl-Wewalka M, Schmid M et al. (2024) Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure. Sci Rep 14(1):11309","journal-title":"Sci Rep"},{"key":"362_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jointm.2025.05.001","author":"R Ferrer","year":"2025","unstructured":"Ferrer R, Thielmann M, Kribben A, Unglaube M, Tyczynski B, Kreutz J et al. (2025) The international, prospective CytOSorb\u24c7 treatMent Of critically ill patientS (COSMOS) registry: interim results from the first 150 patients. J Intensive Med. https:\/\/doi.org\/10.1016\/j.jointm.2025.05.001","journal-title":"J Intensive Med"},{"issue":"11\u201312","key":"362_CR13","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1159\/000532059","volume":"52","author":"C Grafe","year":"2023","unstructured":"Grafe C, Paal M, Winkels M, Irlbeck M, Liebchen U, Scharf C (2023) Correlation between bilirubin elimination with the cytokine adsorber CytoSorb(R) and mortality in critically ill patients with hyperbilirubinemia. Blood Purif 52(11\u201312):849\u201356","journal-title":"Blood Purif"},{"issue":"1","key":"362_CR14","doi-asserted-by":"publisher","first-page":"10190","DOI":"10.1038\/s41598-021-89712-4","volume":"11","author":"C Scharf","year":"2021","unstructured":"Scharf C, Liebchen U, Paal M, Becker-Pennrich A, Irlbeck M, Zoller M et al. (2021) Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot study. Sci Rep 11(1):10190","journal-title":"Sci Rep"},{"issue":"9","key":"362_CR15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1177\/08850666251331905","volume":"40","author":"G Berlot","year":"2025","unstructured":"Berlot G, Carocci P, Votrico V, Iacoviello B, Taverna N, Gerini U et al. (2025) Real-world outcomes of hemoadsorption with CytoSorb((R)) in patients with septic shock: insights from a single-center study. J Intensive Care Med 40(9):993\u20131000","journal-title":"J Intensive Care Med"},{"issue":"3","key":"362_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jama.2016.20328","volume":"317","author":"EP Raith","year":"2017","unstructured":"Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R et al. (2017) Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA 317(3):290\u2013300","journal-title":"JAMA"},{"issue":"7","key":"362_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14072285","volume":"14","author":"D Steindl","year":"2025","unstructured":"Steindl D, Schroeder T, Krannich A, Nee J (2025) Hemoadsorption in the management of septic shock: a systematic review and meta-analysis. J Clin Med 14(7):2285","journal-title":"J Clin Med"},{"issue":"9","key":"362_CR18","first-page":"366","volume":"10","author":"C Rao","year":"2023","unstructured":"Rao C, Preissing F, Thielmann M, Wendt D, Haidari Z, Kalisnik JM et al. (2023) Hemoadsorption using CytoSorb((R)) in patients with infective endocarditis: a German-based budget impact analysis. J Cardiovasc Dev Dis 10(9):366","journal-title":"J Cardiovasc Dev Dis"},{"key":"362_CR19","doi-asserted-by":"crossref","unstructured":"Hawchar F, Rao C, Akil A, Mehta Y, Rugg C, Scheier J et al. The Potential Role of Extracorporeal Cytokine Removal in Hemodynamic Stabilization in Hyperinfl ammatory Shock. Biomedicines 9(7):768","DOI":"10.3390\/biomedicines9070768"},{"issue":"23","key":"362_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237044","volume":"13","author":"M Papp","year":"2024","unstructured":"Papp M, Ince C, Bakker J, Molnar Z (2024) Endothelial protection and improved micro- and macrocirculation with hemoadsorption in critically ill patients. J Clin Med 13(23):7044","journal-title":"J Clin Med"},{"issue":"7","key":"362_CR21","volume":"13","author":"S Jesani","year":"2021","unstructured":"Jesani S, Elkattawy S, Noori MAM, Ayad S, Abuaita S, Gergis K et al. (2021) Vasopressor-induced digital ischemia. Cureus 13(7):e16595","journal-title":"Cureus"},{"key":"362_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.826446","volume":"9","author":"M Jozwiak","year":"2022","unstructured":"Jozwiak M, Geri G, Laghlam D, Boussion K, Dolladille C, Nguyen LS (2022) Vasopressors and risk of acute mesenteric ischemia: a worldwide pharmacovigilance analysis and comprehensive literature review. Front Med (Lausanne) 9:826446","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"362_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.annemergmed.2018.03.039","volume":"72","author":"WH Self","year":"2018","unstructured":"Self WH, Semler MW, Bellomo R, Brown SM, deBoisblanc BP, Exline MC et al. (2018) Liberal versus restrictive intravenous fluid therapy for early septic shock: rationale for a randomized trial. Ann Emerg Med 72(4):457\u201366","journal-title":"Ann Emerg Med"},{"key":"362_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1210219","volume":"14","author":"D Cox","year":"2023","unstructured":"Cox D (2023) Sepsis - it is all about the platelets. Front Immunol 14:1210219","journal-title":"Front Immunol"},{"issue":"2","key":"362_CR25","first-page":"93","volume":"54","author":"CI Brozat","year":"2025","unstructured":"Brozat CI, Zoller M, Frank S, Bruegel M, Grafe C, Rebholz D et al. (2025) Albumin and platelet loss during the application of CytoSorb(R) in critically ill patients: a post hoc analysis of the Cyto-SOLVE trial. Blood Purif 54(2):93\u2013101","journal-title":"Blood Purif"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-026-00362-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-026-00362-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-026-00362-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:40:35Z","timestamp":1773240035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44158-026-00362-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["362"],"URL":"https:\/\/doi.org\/10.1186\/s44158-026-00362-2","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The registry is being conducted in compliance with ISO 14155:2020, the Declaration of Helsinki, and the principles of Good Clinical Practice (GCP), as outlined in the International Conference on Harmonization (ICH) E6 Guidelines for GCP, along with all relevant local legal requirements. Before the registry begins, approval must be obtained from the Institutional Review Board (IRB)\/Independent Ethics Committee (IEC) for the study protocol, sample informed consent form (ICF), and any documents related to patient information or recruitment methods, such as advertisements. Any subsequent amendments to the protocol or changes to the ICF must also be submitted for approval by the IRB\/IEC. The initial international ethics approval was from IRB \u201cComit\u00e9 de \u00c9tica de Investigaci\u00f3n con Medicamentos del Hospital Universitario Vall d\u2019Hebron\u201d with the approval number PR(AG)86\/2022 (28 March 2022). Each participating center is required to obtain approval from its respective IRB before study activation.Written informed consent was obtained from all subjects or legally authorized representatives involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FST, GB, JH, AK, JLT, DT, and RF have consulting contracts with CytoSorbents Corporation and CytoSorbents Medical Inc. AB has received reimbursements for travelling expenses and honoraria for presentations from CytoSorbents Europe GmbH. JK has received honoraria for presentation from CytoSorbents Europe GmbH. TeK and JS are full-time employees of CytoSorbents Europe GmbH. END and WF are full-time employees of CytoSorbents Corporation and CytoSorbents Medical Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}